Cumberland Pharmaceuticals
CPIX
27 hedge funds and large institutions have $23M invested in Cumberland Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0.22% more ownership
Funds ownership: 29.16% → 29.38% (+0.22%)
4% less funds holding
Funds holding: 28 → 27 (-1)
14% less capital invested
Capital invested by funds: $26.6M → $23M (-$3.61M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$274K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$189K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.16K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.22K |
| 5 |
Renaissance Technologies
New York
|
+$1.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
-$528K |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$80K |
| 3 |
FGAM
Financial Gravity Asset Management
Lakeway,
Texas
|
-$21.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$18.3K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$16.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DGHMC
26
Dalton, Greiner, Hartman, Maher & Co
New York
| – | -$528K | -89,100 | Closed |
|
|
PPA
27
Parametric Portfolio Associates
Seattle,
Washington
| – | -$80K | -13,556 | Closed |
|
28
Victory Capital Management
San Antonio,
Texas
| – | -$9K | -1,523 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -178 | Closed |
|
30
Barclays
London,
United Kingdom
| – | -$433 | -82 | -96% |
|
CPIX Hedge Fund Activity: Q4 2019 in Review
27 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q4 2019, worth a combined $23M — down 14% from $26.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CPIX and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 5 added.
The largest buyer was Ariel Investments, adding an estimated $274K. The largest seller was Dalton, Greiner, Hartman, Maher & Co, exiting entirely with an estimated $528K sold.
- 27 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q4 2019, down from 28 in Q3 2019.
- Funds reported $23M of Cumberland Pharmaceuticals stock for Q4 2019, down 14% quarter-over-quarter.
- 3 funds opened new Cumberland Pharmaceuticals positions in Q4 2019 and 4 closed out, a net change of -1 holder.
- The largest Cumberland Pharmaceuticals buyer in Q4 2019 was Ariel Investments, an estimated $274K added.
- The largest Cumberland Pharmaceuticals seller in Q4 2019 was Dalton, Greiner, Hartman, Maher & Co, an estimated $528K sold.
Based on aggregated 13F filings for Q4 2019.